Trials / Recruiting
RecruitingNCT05666960
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
A Single and Repeat Dosing Study of the Safety, Drug Exposure, and Clinical Activity of R-3750 in Patients With Mild to Moderate Ulcerative Colitis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Rise Therapeutics LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Conditions
- Ulcerative Colitis Chronic Mild
- Ulcerative Colitis Chronic Moderate
- Ulcerative Colitis Chronic
- Ulcerative Colitis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-3750 | Probiotic |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2026-07-01
- Completion
- 2026-10-01
- First posted
- 2022-12-28
- Last updated
- 2026-01-29
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05666960. Inclusion in this directory is not an endorsement.